Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068432 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 11
- Study locations
NCT00068432 is a Phase 2 study of Pancreatic Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 28 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 11 study locations across 10 states.
The verdict
NCT00068432, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 11
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gemcitabine with celecoxib may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with celecoxib works in treating patients with metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG Celecoxib
- DRUG Gemcitabine Hydrochloride
Study Locations (11)
Missouri
- CCOP - Kansas City - Kansas City
- CCOP - Cancer Research for the Ozarks - Springfield
Arkansas
- Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith
Florida
- M.D. Anderson Cancer Center - Orlando - Orlando
Georgia
- CCOP - Atlanta Regional - Atlanta
Illinois
- CCOP - Carle Cancer Center - Urbana
Kansas
- CCOP - Wichita - Wichita
Ohio
- CCOP - Dayton - Dayton
Oregon
- CCOP - Columbia River Oncology Program - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068432
The ClinicalTrials.gov registry entry for NCT00068432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 2 interventions - of which Celecoxib is the first listed.
NCT00068432 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Missouri, Arkansas, Florida.
Frequently Asked Questions
What is clinical trial NCT00068432 about?
NCT00068432 is a clinical study titled "Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of pancreatic cancer by stopping blood flow to the tumor and blocking the enzymes necessary for tumor cell growth. Combining gem...
What is the current status of trial NCT00068432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2003-12. Estimated completion is 2005-07.
What conditions does trial NCT00068432 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00068432?
The interventions under investigation include: Celecoxib (DRUG), Gemcitabine Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00068432?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00068432 being conducted?
This trial has 11 study locations across Arkansas, Florida, Georgia, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.